KalVista Pharmaceuticals, Inc. (KALV): Price and Financial Metrics


KalVista Pharmaceuticals, Inc. (KALV): $19.38

0.13 (+0.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

KALV POWR Grades


  • KALV scores best on the Value dimension, with a Value rank ahead of 49.95% of US stocks.
  • The strongest trend for KALV is in Stability, which has been heading down over the past 31 weeks.
  • KALV ranks lowest in Momentum; there it ranks in the 5th percentile.

KALV Stock Summary

  • The ratio of debt to operating expenses for KalVista Pharmaceuticals Inc is higher than it is for about only 6.51% of US stocks.
  • KALV's price/sales ratio is 143.41; that's higher than the P/S ratio of 97.06% of US stocks.
  • Revenue growth over the past 12 months for KalVista Pharmaceuticals Inc comes in at -67.57%, a number that bests just 3.89% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to KalVista Pharmaceuticals Inc are GSIT, CERC, MRUS, AUTL, and RNA.
  • Visit KALV's SEC page to see the company's official filings. To visit the company's web site, go to www.kalvista.com.

KALV Valuation Summary

  • In comparison to the median Healthcare stock, KALV's price/earnings ratio is 151.88% lower, now standing at -17.9.
  • KALV's price/earnings ratio has moved down 8.2 over the prior 76 months.
  • Over the past 76 months, KALV's EV/EBIT ratio has gone down 6.8.

Below are key valuation metrics over time for KALV.

Stock Date P/S P/B P/E EV/EBIT
KALV 2021-05-28 171.6 11.2 -17.3 -16.8
KALV 2018-03-21 32.2 3.9 -5.7 -2.7
KALV 2017-09-11 NA 2.6 -4.3 -2.7
KALV 2016-11-18 822.7 0.5 -0.8 0.8
KALV 2015-10-19 3441.4 1.7 -7.5 -3.2
KALV 2015-04-22 5627.6 -3.7 -12.2 -13.5

KALV Price Target

For more insight on analysts targets of KALV, see our KALV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.71 Average Broker Recommendation 1.29 (Strong Buy)

KALV Stock Price Chart Interactive Chart >

Price chart for KALV

KALV Price/Volume Stats

Current price $19.38 52-week high $45.00
Prev. close $19.25 52-week low $12.01
Day low $18.55 Volume 42,615
Day high $19.39 Avg. volume 520,034
50-day MA $20.41 Dividend yield N/A
200-day MA $23.83 Market Cap 473.61M

KalVista Pharmaceuticals, Inc. (KALV) Company Bio


KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. The company is based in Cambridge, Massachusetts.


KALV Latest News Stream


Event/Time News Detail
Loading, please wait...

KALV Latest Social Stream


Loading social stream, please wait...

View Full KALV Social Stream

Latest KALV News From Around the Web

Below are the latest news stories about KalVista Pharmaceuticals Inc that investors may wish to consider to help them evaluate KALV as an investment opportunity.

KalVista Pharmaceuticals Reports First Fiscal Quarter Results

CAMBRIDGE, Mass. & SALISBURY, England, September 09, 2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2021.

Yahoo | September 9, 2021

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England, September 02, 2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on September 1, 2021 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Yahoo | September 2, 2021

KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England, August 23, 2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on clinical trial progress for KVD824 in development for oral prophylactic treatment of hereditary angioedema (HAE).

Yahoo | August 23, 2021

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista''s board of directors granted four newly-hired employees inducement options to purchase an

FinanzNachrichten | August 9, 2021

Hedge Funds Are Crazy About KalVista Pharmaceuticals, Inc. (KALV)

No summary available.

Insider Monkey | July 19, 2021

Read More 'KALV' Stories Here

KALV Price Returns

1-mo 1.52%
3-mo -30.86%
6-mo -40.15%
1-year 44.63%
3-year 13.67%
5-year 182.51%
YTD 2.05%
2020 6.63%
2019 -9.82%
2018 102.56%
2017 37.91%
2016 -86.05%

Continue Researching KALV

Want to see what other sources are saying about KalVista Pharmaceuticals Inc's financials and stock price? Try the links below:

KalVista Pharmaceuticals Inc (KALV) Stock Price | Nasdaq
KalVista Pharmaceuticals Inc (KALV) Stock Quote, History and News - Yahoo Finance
KalVista Pharmaceuticals Inc (KALV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.7073 seconds.